$CYTR CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Licensee Orphazyme A/S CytRx Eligible to Receive up to $120 Million in Future Milestones, Plus Single and Double-Digit Royalties, From Arimoclomol Licensing Agreement CytRx Net Operating Losses Will Shelter at Least $250 Million of Potential Future Pre-Tax Profits The following are Orphazyme's expected pipeline milestones and projections: Niemann-Pick disease Type C (NPC): Amyotrophic Lateral Sclerosis (ALS): Sporadic Inclusion Body Myositis (sIBM): Gaucher Disease Parkinson's Disease
1
1
1 Like